NETEC Resource Library

Research resources

This page contains research resources related to developing vaccine studies and therapeutics and other research resources below. Follow the development of the various SARS-COV-2 vaccines with the Coronavirus Vaccine Tracker managed by The New York Times.

Research resources: Therapeutics

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19

Monoclonal Antibody Therapy

Monoclonal Antibody Therapy

NETEC COVID-19 Webinar Series (11/25/20)/Online Course: Monoclonal Antibody Therapeutics: How to Operationalize mAB Therapy at Your Facility

Monoclonal Antibody Therapeutics: How to Operationalize mAB Therapy at Your Facility (November 25, 2020)

NETEC COVID-19 Webinar Series (11/18/20)/Online Course: COVID-19 Therapeutics

COVID-19 Therapeutics (November 18, 2020)

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of CASIRIVIMAB and IMDEVIMAB

Fact Sheet for Health Care Providers: EUA of CASIRIVIMAB and IMDEVIMAB

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of BARICITINIB

Fact Sheet for Heath Care Providers: Emergency Use Authorization (EUA) of Bamlanivimab

Fact Sheet for Heath Care Providers: EUA of Bamlanivimab

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of multiFiltrate PRO System and multiBic/multiPlus Solutions during the COVID-19 Pandemic

act Sheet for Health Care Providers: EUA of multiFiltrate PRO System and multiBic/multiPlus Solutions during the COVID-19 Pandemic

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of FRESENIUS PROPOVEN 2% Emulsion

Fact Sheet for Health Care Providers: EUA of FRESENIUS PROPOVEN 2% Emulsion

Fact Sheet for Healthcare Providers: REGIOCIT (Sodium Chloride and Sodium Citrate Renal Replacement and Regional Anticoagulant solution)

Fact Sheet for Healthcare Providers: REGIOCIT

Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized Patients

Fact Sheet for Health Care Providers: EUA of COVID-19 Convalescent Plasma for Treatment of COVID-19 in Hospitalized Patients

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Remdesivir for the Treatment of Covid-19 — Final Report

Remdesivir for the Treatment of Covid-19 — Final Report

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Mild/Moderate 2019-nCoV Remdesivir RCT

Mild/Moderate 2019-nCoV Remdesivir RCT

Severe 2019-nCoV Remdesivir RCT

Severe 2019-nCoV Remdesivir RCT

Adaptive COVID-19 Treatment Trial (ACTT)

Adaptive COVID-19 Treatment Trial (ACTT)

Vaccine Studies:

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

COVID-19 Vaccine Comparison Chart

COVID-19 Vaccine Comparison Chart

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Bilateral superior ophthalmic vein thrombosis, ischaemic stroke, and immune thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination

Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

SARS-CoV-2 Infection after Vaccination in Health Care Workers in California

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001)

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults...

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years...

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV...

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine...

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report...

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older...

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

Other Research resources:

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

Nextstrain - Novel coronavirus (2019-nCoV) situation reports and latest data and analysis

Nextstrain - Novel coronavirus (2019-nCoV) situation reports and latest data and analysis

Nextstrain - Genetic diversity of betacoronaviruses including novel coronavirus from Wuhan

Nextstrain - Genetic diversity of betacoronaviruses including novel coronavirus from Wuhan

Nextstrain - Genomic epidemiology of novel coronavirus (nCoV)

Nextstrain - Genomic epidemiology of novel coronavirus (nCoV)

Nextstrain - Phylogeny of SARS-like betacoronaviruses including novel coronavirus from Wuhan

Nextstrain - Phylogeny of SARS-like betacoronaviruses including novel coronavirus from Wuhan

SeroTracker: a global SARS-CoV-2 seroprevalence dashboard

SeroTracker: a global SARS-CoV-2 seroprevalence dashboard